Since its first identification in December 2019 in Wuhan, the Severe Acute Respiratory Syndrome-Corona Virus-Type 2 (SARS-CoV-2) virus has spread globally causing the era of COVID 19 pandemic [
1]. SARS-CoV-2 outbreak has caused detrimental effects not only on the global healthcare systems but also on social and economic aspect of human life [
2]. The pandemic has affected various sectors including agriculture, manufacturing industry, education and finance industry, tourism and so on [
2]. As vaccination is one of the most effective response to such outbreak, many scientists across the world got involved in the race to develop successful anti-SARS-CoV-2 vaccines. Among the different vaccines developed against SARS-CoV-2, Covishield was the first vaccine approved for emergency use in Nepal. Covishield, also known as ChAdOx1 nCoV-19 vaccine (AZD1222), is a replication-deficient chimpanzee adenoviral vector vaccine that contains SARS-CoV-2 structural surface glycoprotein antigen gene and was developed at Oxford University [
3]. The different clinical trials that were conducted to evaluate the safety and efficacy of Covishield showed that the vaccine was safe and efficacious in the trial population [
3,
4]. Nepal started its first phase vaccination drive starting on Jan 27, 2021, with the COVISHIELD vaccine for frontline health workers [
5]. According to a cross-sectional study conducted at Patan Academy of Health Sciences (PAHS), Nepal to calculate the incidence of Adverse Events Following Immunization (AEFI) observed after the first dose of Covishield vaccine minor AEFIs were seen in 85.1 % of recipients whereas serious AEFI and severe minor AEFI were in 0.06 % and 0.03% recipients, respectively [
5]. In this study, one case of anaphylaxis was observed, however no deaths were reported [
5]. In the EudraVigilance drug safety database there has been reported 62 cases of cerebral venous sinus thrombosis, 24 cases of spanchnic vein thrombosis, 18 cases of the fatal thrombotic events among 25 million recipients of the ChAdOx1 nCov-19 vaccine [
6]. There have been 2 reported cases of deep vein thrombosis and one case of bilateral superior ophthalmic vein thrombosis after ChAdOx1 nCoV-19 vaccination [
7,
8]. Here in this article, we report two cases of Superficial Vein Thrombosis (SVT) for the first time in the literature after vaccination with the ChAdOx1 nCoV-19 vaccine.